Study: NCT00620659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: MK0249
Description: Patients will be assigned to receive MK0249 film coated tablet (FCT). The doses of MK0249 that are included for possible investigation (depending upon an adaptive allocation process) are 3 mg, 5 mg, 8 mg, 10 mg, and 12 mg. Study medication will be taken for 14 days, during each of the 3 treatment periods, by mouth (po) once a day (qd).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: MK0249
Description: Patients will be assigned to receive MK0249 film coated tablet (FCT). The doses of MK0249 that are included for possible investigation (depending upon an adaptive allocation process) are 3 mg, 5 mg, 8 mg, 10 mg, and 12 mg. Study medication will be taken for 14 days, during each of the 3 treatment periods, by mouth (po) once a day (qd).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: MK0249
Description: Patients will be assigned to receive MK0249 film coated tablet (FCT). The doses of MK0249 that are included for possible investigation (depending upon an adaptive allocation process) are 3 mg, 5 mg, 8 mg, 10 mg, and 12 mg. Study medication will be taken for 14 days, during each of the 3 treatment periods, by mouth (po) once a day (qd).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: MK0249
Description: Patients will be assigned to receive MK0249 film coated tablet (FCT). The doses of MK0249 that are included for possible investigation (depending upon an adaptive allocation process) are 3 mg, 5 mg, 8 mg, 10 mg, and 12 mg. Study medication will be taken for 14 days, during each of the 3 treatment periods, by mouth (po) once a day (qd).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: MK0249
Description: Patients will be assigned to receive MK0249 film coated tablet (FCT). The doses of MK0249 that are included for possible investigation (depending upon an adaptive allocation process) are 3 mg, 5 mg, 8 mg, 10 mg, and 12 mg. Study medication will be taken for 14 days, during each of the 3 treatment periods, by mouth (po) once a day (qd).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: MK0249
Description: Patients will be assigned to receive MK0249 film coated tablet (FCT). The doses of MK0249 that are included for possible investigation (depending upon an adaptive allocation process) are 3 mg, 5 mg, 8 mg, 10 mg, and 12 mg. Study medication will be taken for 14 days, during each of the 3 treatment periods, by mouth (po) once a day (qd).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: placebo
Description: Placebo; Patients will be assigned to receive placebo, across 3 treatment periods. Study medication will be taken for 14 days, during each of the 3 treatment periods, po qd.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: placebo
Description: Placebo; Patients will be assigned to receive placebo, across 3 treatment periods. Study medication will be taken for 14 days, during each of the 3 treatment periods, po qd.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: placebo
Description: Placebo; Patients will be assigned to receive placebo, across 3 treatment periods. Study medication will be taken for 14 days, during each of the 3 treatment periods, po qd.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: placebo
Description: Placebo; Patients will be assigned to receive placebo, across 3 treatment periods. Study medication will be taken for 14 days, during each of the 3 treatment periods, po qd.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: placebo
Description: Placebo; Patients will be assigned to receive placebo, across 3 treatment periods. Study medication will be taken for 14 days, during each of the 3 treatment periods, po qd.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: placebo
Description: Placebo; Patients will be assigned to receive placebo, across 3 treatment periods. Study medication will be taken for 14 days, during each of the 3 treatment periods, po qd.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: modafinil
Description: Patients will be assigned to receive modafinil 200mg oral compressed tablet (OCT), across 3 treatment periods. Study medication will be taken for 14 days, during each of the 3 treatment periods, po qd.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: modafinil
Description: Patients will be assigned to receive modafinil 200mg oral compressed tablet (OCT), across 3 treatment periods. Study medication will be taken for 14 days, during each of the 3 treatment periods, po qd.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: modafinil
Description: Patients will be assigned to receive modafinil 200mg oral compressed tablet (OCT), across 3 treatment periods. Study medication will be taken for 14 days, during each of the 3 treatment periods, po qd.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: modafinil
Description: Patients will be assigned to receive modafinil 200mg oral compressed tablet (OCT), across 3 treatment periods. Study medication will be taken for 14 days, during each of the 3 treatment periods, po qd.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: modafinil
Description: Patients will be assigned to receive modafinil 200mg oral compressed tablet (OCT), across 3 treatment periods. Study medication will be taken for 14 days, during each of the 3 treatment periods, po qd.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: modafinil
Description: Patients will be assigned to receive modafinil 200mg oral compressed tablet (OCT), across 3 treatment periods. Study medication will be taken for 14 days, during each of the 3 treatment periods, po qd.